Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol.
Iwaki M, Kobayashi T, Nogami A, Ogawa Y, Imajo K, Sakai E, Nakada Y, Koyama S, Kurihashi T, Oza N, Kohira T, Okada M, Yamaguchi Y, Iwane S, Kageyama F, Sasada Y, Matsushita M, Tadauchi A, Murohisa G, Nagasawa M, Sato S, Maeda K, Furuta K, Shigefuku R, Seko Y, Tobita H, Kawata K, Kawanaka M, Sugihara T, Tamaki N, Iwasa M, Kawaguchi T, Itoh Y, Kawaguchi A, Takahashi H, Nakajima A, Yoneda M. Iwaki M, et al. Among authors: sato s. BMJ Open. 2024 Nov 24;14(11):e088862. doi: 10.1136/bmjopen-2024-088862. BMJ Open. 2024. PMID: 39581726 Free PMC article. Clinical Trial.
Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: machine-learning analysis of the DESIRES trial.
Kuzumi A, Oba K, Ebata S, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Kage H, Sato S, Yoshizaki A. Kuzumi A, et al. Among authors: sato s. Rheumatology (Oxford). 2024 Dec 24:keae716. doi: 10.1093/rheumatology/keae716. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39718799
An epidemiological study on the factors including genetic polymorphism influencing ALT >30 U/L and liver fibrosis progression in metabolic dysfunction-associated steatotic liver disease among the general population.
Sato S, Iino C, Sasada T, Soma G, Furusawa K, Yoshida K, Sawada K, Mikami T, Fukuda S, Nakaji S, Sakuraba H. Sato S, et al. JGH Open. 2024 Dec 19;8(12):e70043. doi: 10.1002/jgh3.70043. eCollection 2024 Dec. JGH Open. 2024. PMID: 39713746 Free PMC article.
12,265 results
You have reached the last available page of results. Please see the User Guide for more information.